Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 18, 2024SKIN The Journal of Cutaneous MedicineOpen Access

Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure

View Full Paper
Ask AI
Bookmark
Share

Authors

APAmy S. PallerLELawrence F. EichenfieldJSJonathan I. Silverberg

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Paller et al. (2024) studied this question.

synapsesocial.com/papers/68e7398bb6db6435876b2d93https://doi.org/10.25251/skin.8.supp.379
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure2024 · 53 citations
  2. 2Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL2026
  3. 3Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years2026 · 5 citations
  4. 4Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)2026
  5. 5Abrocitinib: 1‐Year Real‐Life Experience From the French OMCCI Registry2026